Noventra Pharma TirReta (60mg Multi-Dose Prefilled Pen – Tirzepatide + Retatrutide)

TirReta is a combination formulation supplied in a pre-reconstituted multi-dose pen format for controlled dispensing. It combines tirzepatide, a dual incretin receptor agonist, with retatrutide, a multi-receptor peptide investigated for activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

This combination is investigated for its role in metabolic and endocrine signalling pathways related to energy balance and regulatory processes.

Key Features:

• 60mg combined formulation: tirzepatide + retatrutide

• Multi-receptor activity involving GLP-1, GIP, and glucagon pathways

• Prefilled pen format for controlled and consistent application

• Investigated for roles in metabolic and endocrine signalling pathways

• Studied in relation to energy balance and glucose regulation processes

• Associated in research with metabolic pathway modulation

Suggested Use:
For use under the guidance of a qualified professional. Protocols vary depending on application and individual requirements.

Storage:

• Store at 2–8°C at all times (refrigerated)

• Do not freeze

• Protect from light

• Avoid repeated temperature fluctuations

• Use within a limited timeframe once in use (based on formulation stability)

Important Information:
This product contains investigational components and should be used within appropriate professional and regulatory frameworks. Not recommended for individuals under 18, pregnant or breastfeeding individuals, or those with certain medical conditions. Ensure compliance with applicable regulations prior to use.